Lumen gets $16M for C. diff drug; Flashpoint’s seed round; Amplifier expands Series A
17 Oct 2023
IPO
Plus, Tessellate BIO, led by former Big Pharma execs, comes out of stealth.
Lumen Bioscience gets $16M to advance C. diff therapy:
The Department of Defense
awarded $16.2 million
to the Seattle-based company, which is developing an oral drug to treat and prevent infections with
C. difficile
. It plans to start enrolling 375 patients in a late-stage trial for LMN-201 by the end of the year.
Flashpoint’s $10M:
Flashpoint Therapeutics on Tuesday announced a $10 million seed round, led by Riyadh-based Beta Lab. The funds are expected to help advance the company’s first cancer therapy and select a second candidate. Flashpoint’s platform is based on work out of Chad Mirkin’s lab at Northwestern University’s International Institute for Nanotechnology.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.